Which has the lower trailing P/E, BMY or GSK?

BMY has the lower trailing P/E: BMY trades at 13.47 and GSK at 14.87. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BMY or GSK?

Over the past five years, BMY grew revenue faster — BMY at a 2.08% CAGR versus GSK at 1.38%.

Does BMY or GSK pay a bigger dividend?

BMY yields 4.12% and GSK yields 3.86% based on trailing dividends and the latest price.

Is BMY or GSK more profitable?

BMY runs the higher net margin — BMY at 18.87% versus GSK at 14.52%.

How have BMY and GSK total returns compared?

Over the past 10 years, BMY delivered 5.01% and GSK delivered 5.71% annualized total return. Past performance doesn't predict future results.

Bristol-Myers Squibb Company (BMY) vs GSK plc (GSK)

A side-by-side comparison of Bristol-Myers Squibb Company and GSK plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 4, 2026. Differences are shown without an overall score or investment verdict.

BMY

Bristol-Myers Squibb Company

$124.91B

$61.15HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT

GSK

GSK plc

$94.22B

$47.03HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT

Total return — BMY vs GSK

growth of $100 · dividends reinvested · last 10y

BMY +63.2% (+5.0%/yr)GSK +74.6% (+5.7%/yr)GSK compounded faster over this window

BMY GSK

BMY vs GSK: by the numbers

•BMY is the larger company ($124.91B vs $94.22B market cap).
•BMY trades at the lower trailing earnings multiple (13.47 vs 14.87 P/E), one valuation lens rather than an overall verdict.
•BMY converts more revenue to profit (18.87% vs 14.52% net margin).
•BMY grew revenue faster over the past five years (2.08% vs 1.38% CAGR).
•BMY pays the higher dividend yield (4.12% vs 3.86%).

Metrics side by side

Valuation

Metric	BMY	GSK
P/E ratio	13.47	14.87
Forward P/E	8.79	N/A
P/S ratio	2.54	2.13
P/B ratio	5.60	4.05
EV / EBITDA	9.41	7.68
FCF yield	9.16%	9.90%

Profitability

Metric	BMY	GSK
Gross margin	70.16%	72.71%
Operating margin	28.27%	20.72%
Net margin	18.87%	14.52%
ROE	41.59%	27.67%
ROIC	15.47%	13.95%

Dividends

Metric	BMY	GSK
Dividend yield	4.12%	3.86%
Payout ratio	55.51%	57.45%

Growth (annualized)

Metric	BMY	GSK
Revenue CAGR (5Y)	2.08%	1.38%
EPS CAGR (5Y)	N/A	-0.71%
FCF CAGR (5Y)	-0.95%	-2.45%
Total return CAGR (5Y)	4.79%	8.61%

Frequently asked

Which has the lower trailing P/E, BMY or GSK?: BMY has the lower trailing P/E: BMY trades at 13.47 and GSK at 14.87. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BMY or GSK?: Over the past five years, BMY grew revenue faster — BMY at a 2.08% CAGR versus GSK at 1.38%.
Does BMY or GSK pay a bigger dividend?: BMY yields 4.12% and GSK yields 3.86% based on trailing dividends and the latest price.
Is BMY or GSK more profitable?: BMY runs the higher net margin — BMY at 18.87% versus GSK at 14.52%.
How have BMY and GSK total returns compared?: Over the past 10 years, BMY delivered 5.01% and GSK delivered 5.71% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BMY analysis Full GSK analysis Interactive comparison tool

Dig into the metrics

Bristol-Myers Squibb P/E ratio GSK P/E ratio Bristol-Myers Squibb dividend yield GSK dividend yield Bristol-Myers Squibb ROE GSK ROE Bristol-Myers Squibb operating margin GSK operating margin Bristol-Myers Squibb revenue growth GSK revenue growth Bristol-Myers Squibb free cash flow GSK free cash flow

Bristol-Myers Squibb & GSK appear in these rankings

Highest Dividend Yield Stocks Highest ROE Stocks Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 4, 2026.